Reumachlor
Categorie
Reumachlor Les marques, Reumachlor Analogs
- 3377 RP opalate
- Amokin
- Aralen
- Aralen HCl
- Arechin
- Arthrochin
- Artrichin
- Avlochlor
- Avloclor
- Bemaco
- Bemaphate
- Bemasulph
- Benaquin
- Bipiquin
- Capquin
- Chemochin
- Chingamin
- Chloraquine
- Chlorochin
- Chlorochine
- Chloroquina
- Chloroquine (VAN)
- Chloroquine Phosphate
- Chloroquinium
- Chlorquin
- Cidanchin
- Clorochina
- Cocartrit
- Delagil
- Dichinalex
- Elestol
- Gontochin
- Heliopar
- Hydroxychloroquine Sulfate
- Imagon
- Iroquine
- Klorokin
- Lapaquin
- Malaquin
- Malaren
- Malarex
- Mesylith
- Neochin
- Nivachine
- Nivaquine
- Nivaquine B
- Nivaquine [as sulfate]
- Pfizerquine
- Plaquenil
- Quinachlor
- Quinagamin
- Quinagamine
- Quinercyl
- Quingamine
- Quinilon
- Quinoscan
- Resochen
- Resochin
- Resoquina
- Resoquine
- Reumachlor
- Reumaquin
- Roquine
- Sanoquin
- Silbesan
- Siragan
- Solprina
- Sopaquin
- Tanakan
- Tresochin
- Trochin
Reumachlor Les marques melange
Reumachlor Formule chimique
C18H26ClN3
Reumachlor RX lien
http://www.rxlist.com/cgi/generic2/hquine2.htm
Reumachlor FDA fiche
Reumachlor msds (fiche de securite des materiaux)
Reumachlor Synthese de reference
Aucune information disponible
Reumachlor Poids moleculaire
319.872 g/mol
Reumachlor Point de fusion
289 oC
Reumachlor H2O Solubilite
10,6 mg / L
Reumachlor Etat
Solid
Reumachlor LogP
4.474
Reumachlor Formes pharmaceutiques
Tablet
Reumachlor Indication
Pour le traitement suppressif et de crises aiguës de paludisme à P. vivax, P. malariae, P. ovale et des souches sensibles de P. falciparum, l'agent de deuxième ligne dans le traitement de la polyarthrite rhumatoïde
Reumachlor Pharmacologie
La chloroquine est le prototype de médicament anti paludisme, la plus largement utilisée pour traiter tous les types de paludisme, sauf pour les maladies causées par la chloroquine de Plasmodium falciparum résistant. Il est très efficace contre les formes érythrocytaires de Plasmodium vivax, Plasmodium ovale et Plasmodium malariae, les souches sensibles de Plasmodium falciparum et des gamétocytes de Plasmodium vivax. Etre alcalin, le médicament atteint forte concentration dans les vacuoles alimentaires du parasite et soulève son pH. Il se trouve à induire l'agglutination rapide du pigment. La chloroquine inhibe l'enzyme polymérase parasitaires hème qui convertit l'hème toxiques dans non toxique hemazoin, ce qui entraîne l'accumulation de toxiques dans l'hème du parasite. Il peut également interférer avec la biosynthèse des acides nucléiques.
Reumachlor Absorption
Complètement absorbé par les voies gastro-intestinales
Reumachlor Toxicite
Aucune information disponible
Reumachlor Information pour les patients
PATIENT INFORMATION
Complete blood cell counts should be made periodically if patients are given prolonged therapy. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered. The drug should be administered with caution to patients having G-6-PD (glucose-6 phosphate dehydrogenase) deficiency.
In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patient closely observed.
Since this drug is known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs.
Patients with history of epilepsy should be advised about the risk of chloroquine provoking seizures.
Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother.
Irreversible retinal damage has been observed in some patients who had received long-term or high-dosage 4-aminoquinoline therapy. Retinopathy has been reported to be dose related.
Follow Rxlist link and drugs.com link for detailed patient information.
Complete blood cell counts should be made periodically if patients are given prolonged therapy. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered. The drug should be administered with caution to patients having G-6-PD (glucose-6 phosphate dehydrogenase) deficiency.
In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patient closely observed.
Since this drug is known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs.
Patients with history of epilepsy should be advised about the risk of chloroquine provoking seizures.
Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother.
Irreversible retinal damage has been observed in some patients who had received long-term or high-dosage 4-aminoquinoline therapy. Retinopathy has been reported to be dose related.
Follow Rxlist link and drugs.com link for detailed patient information.
Reumachlor Organismes affectes
Plasmodium
